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Abstract
To estimate endemic areas for Crimean-Congo haemorrhagic
fever (CCHF) in Greece, a country-wide seroepidemiological
study was conducted, and 1611 human sera were prospectively
collected along with data regarding possible risk factors for
acquisition of infection, and tested for CCHF virus IgG antibod-
ies by ELISA. The overall seroprevalence was 4.2%, with signiﬁ-
cant differences among prefectures, ranging from 0 to 27.5%.
Multivariate analysis revealed that slaughtering and agricultural
activities were signiﬁcant risk factors for CCHFV seropositivity.
The signiﬁcantly high seroprevalence in speciﬁc prefectures,
together with the extremely low number of CCHF cases, sug-
gest that this phenomenon might be strain-related.
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Crimean-Congo haemorrhagic fever virus (CCHFV, genus
Nairovirus, family Bunyaviridae) causes an acute febrile dis-
ease in humans, often accompanied by haemorrhagic manifes-
tations with fatality rate ranging from 5 to 30%. Humans are
infected through the bites of ixodid ticks or by direct
contact with blood or tissues of CCHF patients or viraemic
livestock [1]. CCHF is the most widely distributed tick-borne
viral infection, with cases being reported from different parts
of Asia, Africa, the Middle East, Eastern Europe and the Bal-
kans [2].
Greece is a Balkan country with a population of 11.3 mil-
lion. CCHF is endemic in neighbouring countries (Albania,
Kosovo, Bulgaria and Turkey), where sporadic cases or out-
breaks occur almost annually [3–7]. A seroprevalence study
conducted in Greece during 1981–1988 in 25 of the 54 pre-
fectures among 3388 persons showed that 1.0% (range 0–
9.6%) of the population had CCHFV antibodies [8]. A
CCHFV strain, AP92, was isolated from Rhipicephalus bursa
ticks collected in 1975 from goats in Vergina village in north-
ern Greece [9]; the seroprevalence among 64 residents of
Vergina was 6.1% [10]. In June 2008, CCHF emerged in
Greece when a fatal case was observed in Komotini city (Ro-
dopi prefecture) in north-eastern Greece [11]. The causative
strain (Rodopi strain) differs genetically from the AP92 strain,
which is considered as non-pathogenic or of low pathogenic-
ity for humans [12]. A preliminary serological survey among
1178 residents of ﬁve prefectures around the region where
the ﬁrst CCHF case was reported, showed a prevalence of
3.4%, with the highest prevalence in Rodopi and Evros pre-
fectures (4.95 and 4.49%, respectively) [13]. The aim of the
present study was to estimate the seroprevalence against
CCHFV across Greece, and to detect possible endemic foci
of the disease.
Serum samples were prospectively collected during June
2009 to December 2010 from 1611 residents of 28 prefec-
tures in Greece. The participants were selected randomly
among patients referred to primary health-care centres for
blood testing with no signs of infectious diseases, regardless of
CCHF risk factors. It was requested that attention be paid to
enrolling people from all age groups. Oral consent was given
by all participants and a questionnaire was completed regard-
ing age, sex, occupation, contact with animals, hunting, slaugh-
tering, history of tick bite and other activities or data related
to an increased risk of CCHF infection [14]. The present study
has been approved by the Bioethics Committee of the Medical
School of Aristotle University of Thessaloniki.
Serum samples were tested for CCHFV IgG antibodies by
commercial ELISA (Vektor-Best, Koltsovo, Novosibirsk, Rus-
sia) according to the instructions of the manufacturer. This
kit has been previously compared with an in-house ELISA
(US Army Medical Research Institute for Infectious Diseases,
Fort Detrick, MD, USA) and results were comparable in all
samples tested [15]. The data were analysed using SPSS 17.0.
The association between the categorical variables was esti-
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mated by chi-square test or Fisher’s exact test when the
expected count was <5. Multivariable logistic regression anal-
ysis was performed to identify potential risk factors for
CCHFV infection. The ﬁnal multivariable model was built
with a stepwise backward selection for variables with univari-
ate p <0.20. The ﬁnal multivariable model was re-estimated
adjusting for region. The OR and 95% CI were obtained and
statistical signiﬁcance was deﬁned as a two-tailed p £0.05.
In total, 68 (4.2%) participants were carrying CCHFV IgG
antibodies. The mean age of seropositive and seronegative
persons was 73.6 years (range 26–90) and 55.6 years (range
2–96), respectively (p <0.001). Seroprevalence differed signif-
icantly among prefectures of Greece (p <0.001) ranging from
0 to 27.5% (Fig. 1). The prefectures of Grevena, Fthiotida
and Thesprotia showed the highest seropositivity (15.4, 11.1
and 27.5%, respectively).
Crude analysis showed that older age, male gender, agri-
cultural activities, contact with goats, sheep and cows, con-
tact with prey, slaughtering, visit to forests, history of tick
bite and the existence of ticks in the workplace were signiﬁ-
cantly associated with seropositivity (Table 1). Multivariable
logistic regression analysis showed that older age (OR 1.10,
95% CI 1.07–1.13, p <0.001), slaughtering (OR 2.06, 95% CI
1.13–3.74, p 0.018) and agricultural activities (OR 2.31, 95%
CI 1.09–4.88, p 0.029) were signiﬁcant risk factors for the
acquisition of CCHFV infection. As in most diseases, there is
increased probability of acquiring the infection with age, so
the main risk factors are slaughtering and agricultural activi-
ties. This fact explains the high seroprevalence in Grevena,
FIG. 1. Distribution of Crimean-Congo haemorrhagic fever virus seroprevalence among prefectures in Greece. The numbers in parenthesis indi-
cate the number of sera tested. An asterisk in ﬁve prefectures indicates that the results were from a previous study [13].
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Fthiotida and Thesprotia prefectures, as livestock husbandry
is the main occupation of residents of these mountainous
regions, and a large proportion of the population comes into
close contact with livestock.
To our knowledge, this is the only country-wide serosur-
vey conducted in a CCHF-endemic country to deﬁne serop-
revelance against CCHFV, as well as risk factors for
acquisition of CCHFV infection. The study presented an
extended circulation of CCHFV in Greece, with wide differ-
ences among prefectures. Comparing our results with those
of the study conducted in the late 1980s [8], marked differ-
ences were observed, as the previous seroprevalences of
0% in the prefectures of Serres, Kastoria, Florina and Mag-
nesia are now 3.0, 7.0, 2.1 and 2.0%, respectively. In addi-
tion, previous seroprevalences of 1.6, 1.0 and 1.0% in the
prefectures of Ioannina, Evritania and Laconia, respectively,
TABLE 1. Univariate logistic
regression analysis of Crimean-
Congo haemorrhagic fever virus
seropositivity in association with
risk factors
IgG positive
(n = 68)
IgG negative
(n = 1543) p value OR 95% CI
Age, median value (IQR) 74.0 (70.3–80.0) 4 58 (42.0–71.0) 76 <0.001 1.09 1.06–1.11
Missing data
Sex 0.036 1.69 1.04–2.77
Male 39 (5.4%) 681 (94.6%)
Female 29 (3.3%) 857 (96.7%) Ref.
Missing data 0 5
Occupation <0.001 3.62 1.87–7.02
Farmer 50 (6.6%) 706 (93.4%)
Other 11 (1.9%) 562 (98.1%) Ref.
Missing data 7 275
Contact with animals 0.020 1.85 1.10–3.10
Yes 46 (5.6%) 777 (94.4%)
No 22 (3.1%) 687 (96.9%) Ref.
Missing data 0 79
Contact with goats 0.001 2.54 1.49–4.33
Yes 21 (8.8%) 219 (91.3%)
No 47 (3.6%) 1245 (96.4%) Ref.
Missing data 0 79
Contact with sheep <0.001 3.94 2.36–6.56
Yes 26 (11.6%) 199 (88.4%)
No 42 (3.2%) 1265 (96.8%) Ref.
Missing data 0 79
Contact with cows <0.001 3.39 1.75–6.56
Yes 12 (12.1%) 87 (87.9%)
No 56 (3.9%) 1377 (96.1%) Ref.
Missing data 0 79
Contact with dogs 0.096 0.57 0.30–1.10
Yes 11 (2.9%) 369 (97.1%)
No 57 (4.9%) 1095 (95.1%) Ref.
Missing data 0 79
Contact with horses 0.945 1.05 0.25–4.44
Yes 2 (4.7%) 41 (95.3%)
No 66 (4.4%) 1423 (95.6%) Ref.
Missing data 0 79
Hunting 0.670 1.21 0.51–2.86
Yes 6 (5.2%) 110 (94.8%)
No 57 (4.3%) 1261 (95.7%) Ref.
Missing data 5 172
Contact with prey 0.001 2.79 1.50–5.19
Yes 18 (8.1%) 203 (91.9%)
No 26 (3.1%) 819 (96.9%) Ref.
Missing data 24 521
Slaughtering <0.001 2.70 1.63–4.47
Yes 27 (8.9%) 276 (91.1%)
No 40 (3.5%) 1103 (96.5%) Ref.
Missing data 1 164
Visit to woods 0.001 2.89 1.56–5.35
Yes 31 (6.8%) 427 (93.2%)
No 16 (2.5%) 637 (97.5%) Ref.
Missing data 21 479
History of tick bite 0.006 2.10 1.24–3.56
Yes 22 (7.7%) 262 (92.3%)
No 46 (3.8%) 1152 (96.2%) Ref.
Missing data 0 129
Ticks around home 0.763 1.11 0.57–2.16
Yes 11 (5.1%) 204 (94.9%)
No 53(4.6%) 1089(95.4%) Ref.
Missing data 4 250
Ticks in workplace 0.017 2.30 1.16–4.54
Yes 12 (9.0%) 122 (91.0%)
No 36 (4.1%) 841 (95.9%) Ref.
Missing data 20 580
IQR, interquartile range; Ref., reference
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are 8.3, 7.5 and 5.9% in the present study, suggesting that
during the past two decades CCHFV was introduced in
some areas of Greece, or its circulation increased remark-
ably in others. In Turkey, where the disease emerged in
2002 with an increasing number of cases, the seropreva-
lence among high-risk populations in the endemic provinces
of Sivas and Tokat is 12.8%, and was associated with a his-
tory of tick bite or tick removal from animals, employment
in animal husbandry or farming [16]. Similar and even higher
seroprevalence was observed in a few prefectures of cen-
tral-western Greece (e.g. Grevena, Fthiotida, Thesprotia)
suggesting that these regions could be pointed out as possi-
ble high-risk areas for CCHFV infection in Greece. Given
that there was only one conﬁrmed diagosis of CCHF in
Greece (despite the fact that more than 500 febrile cases
have been tested for CCHF during the last two decades
and found to be negative), it can be suggested that this phe-
nomenon may be strain-related. Using a mathematical model
it was shown that the ratio of inapparent to clinical CCHF
cases is c. 5 : 1 [17]. Prospective studies are planned to
investigate human febrile cases with even mild thrombocyto-
penia, especially in the areas with the highest seropreva-
lence. In addition, studies in ticks will provide further insight
into the circulation of CCHFV strains in Greece. Favouring
climatic and environmental conditions along with infested
livestock movement should be further investigated to assess
any speciﬁc factors that may contribute to high seropositiv-
ity [18]. Physicians should include CCHF in the differential
diagnosis of febrile cases during spring and summer, espe-
cially when patients present thrombocytopenia and report
animal contact or tick bite.
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